Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients

Area of Science:

• Pharmacology
• Infectious Diseases
• Critical Care Medicine

Background:

• Vancomycin is crucial for treating methicillin-resistant staphylococcal and enterococcal infections, common in intensive care units (ICUs).
• Standard intermittent vancomycin infusion (IVI) faces challenges in achieving timely therapeutic drug levels.
• Continuous vancomycin infusion (CVI) is an alternative method proposed for improved therapeutic target achievement.

Purpose of the Study:

• To compare the clinical benefits of continuous vancomycin infusion (CVI) versus intermittent vancomycin infusion (IVI).
• To evaluate vancomycin efficacy and safety profiles between CVI and IVI in ICU patients.

Main Methods:

• A quasi-experimental study design utilizing propensity score-matched historical controls.
• Adult patients in medical and surgical ICUs receiving vancomycin for indicated infections were analyzed.
• Key outcomes included therapeutic target achievement, supra/subtherapeutic levels, treatment success, mortality, and acute kidney injury (AKI).

Main Results:

• Continuous vancomycin infusion (CVI) demonstrated significantly higher rates of achieving therapeutic targets within 48 hours compared to intermittent vancomycin infusion (IVI).
• CVI was associated with a lower incidence of subtherapeutic vancomycin levels, although supratherapeutic episodes were more frequent.
• Propensity score matching confirmed the superiority of CVI in rapid target attainment and reducing subtherapeutic levels, with no significant differences in treatment success, mortality, or AKI.

Conclusions:

• Continuous vancomycin infusion (CVI) offers advantages over intermittent vancomycin infusion (IVI) due to faster achievement of therapeutic drug levels and fewer subtherapeutic concentrations.
• The study found no significant differences in treatment success, patient mortality, or the incidence of acute kidney injury between the two infusion methods.
• CVI represents a potentially superior method for vancomycin administration in critical care settings, warranting consideration for optimizing patient outcomes.